THE MAJOR PLASMA KALLIKREIN INHIBITOR OF GUINEA-PIG PLASMA

被引:1
|
作者
IMAMURA, T [1 ]
KAMBARA, T [1 ]
机构
[1] KUMAMOTO UNIV, SCH MED, INST MED IMMUNOL, DEPT ALLERGY, KUMAMOTO 860, JAPAN
关键词
PLASMA KALLIKREIN INHIBITOR; (GUINEA PIG PLASMA);
D O I
10.1016/0167-4838(92)90283-J
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A plasma kallikrein inhibitor in guinea pig plasma (KIP) was purified to homogeneity. KIP is a single chain protein and the apparent molecular weight is estimated to be 59 000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In amino acid composition, KIP is similar to human and mouse alpha(1)-proteinase inhibitors and mouse contrapsin. KIP forms an equimolar complex with plasma kallikrein in a dose- and time-dependent fashion. The association rate constants for the inhibition of guinea pig plasma kallikrein by KIP, alpha(2)-macroglobulin, C1-inactivator and antithrombin III were 2.5 +/- 0.3.10(4), 2.4 +/- 0.4.10(4), 6.6 +/- 0.5.10(4) and 9.1 +/- 0.6.10(2), respectively. Comparison of the association rate constants and the normal plasma concentrations of the four inhibitors demonstrates that KIP is ten-times as effective as alpha(2)-MG and other two inhibitors are marginally effective in the inhibition of kallikrein. KIP inhibits trypsin and elastase rapidly, and thrombin and plasmin slowly, but is inactive for chymotrypsin and gland kallikrein. These results suggest that KIP is the major kallikrein inhibitor in guinea pig plasma and the proteinase inhibitory spectrum is unique to KIP in spite of the molecular similarity to alpha(1)-proteinase inhibitor.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 10 条
  • [1] Synergistic antithrombotic effect of a combination of NO donor and plasma kallikrein inhibitor
    Ikarugi, H
    Inoue, A
    Yamashita, T
    Tsuda, Y
    Okada, Y
    Ishii, H
    Yamamoto, J
    THROMBOSIS RESEARCH, 2005, 116 (05) : 403 - 408
  • [2] Practical and Scalable Manufacturing Process for Plasma Kallikrein Inhibitor ASP5069
    Hirasawa, Shun
    Kohmura, Yoshinori
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2020, 24 (12) : 2830 - 2839
  • [3] Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema
    Duckworth, Edward J.
    Murugesan, Nivetha
    Li, Lily
    Rushbrooke, Louise J.
    Lee, Daniel K.
    De Donatis, Gian Marco
    Maetzel, Andreas
    Yea, Christopher M.
    Hampton, Sally L.
    Feener, Edward P.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (09) : 1059 - 1070
  • [4] Discovery and development of plasma kallikrein inhibitors for multiple diseases
    Xie, Zhouling
    Li, Zhen
    Shao, Yanruisheng
    Liao, Chenzhong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 190
  • [5] Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors
    Tsuda, Y
    Tada, M
    Wanaka, K
    Okamoto, U
    Hijikata-Okunomiya, A
    Okamoto, S
    Okada, Y
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2001, 49 (11) : 1457 - 1463
  • [6] Offline derivatization LC-MS/MS method for simultaneous estimation of vanillin and vanillic acid in guinea pig plasma
    Bhutani, Priyadeep
    Murugesan, Senthilkumar
    Kumar, Anoop
    Subramanian, Murali
    Prabhakar, Koiram Rajanna
    BIOANALYSIS, 2018, 10 (03) : 131 - 142
  • [7] Discovery and optimization of orally bioavailable and potent plasma Kallikrein inhibitors bearing a quaternary carbon
    Zhang, Weihe
    Vadlakonda, Satish
    Wu, Minwan
    Chintareddy, Venkat
    Vogeti, L. N.
    Juarez, Luis
    Muppa, Saritha
    Parker, Cynthia
    Kellogg-Yelder, Debra
    Williams, Jason
    Polach, Kevin
    Chen, Xilin
    Raman, Krishnan
    Babu, Y. S.
    Kotian, Pravin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 73
  • [8] Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship
    Okada, Y
    Tsuda, Y
    Tada, M
    Wanaka, K
    Okamoto, U
    Hijikata-Okunomiya, A
    Okamoto, S
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2000, 48 (12) : 1964 - 1972
  • [9] Amino acids and peptides. LIII. Synthesis and biological activities of some pseudo-peptide analogs of PKSI-527, a plasma kallikrein selective inhibitor: The importance of the peptide backbone
    Fukumizu, A
    Tsuda, Y
    Wanaka, K
    Tada, M
    Okamoto, S
    Hijikata-Okunomiya, A
    Okada, Y
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1999, 47 (08) : 1141 - 1144
  • [10] Synthetic peptides and fluorogenic substrates related to the reactive site sequence of Kunitz-type inhibitors isolated from Bauhinia:: Interaction with human plasma kallikrein
    Oliva, MLV
    Santomauro-Vaz, EM
    Andrade, SA
    Juliano, MA
    Pott, VJ
    Sampaio, MU
    Sampaio, CAM
    BIOLOGICAL CHEMISTRY, 2001, 382 (01) : 109 - 113